Karin Schölin Bywall

Karin Schölin Bywall

MSc Public Health
PhD Student

Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.

Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.

E-mail: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49
 

Publications

  • van Overbeeke, Eline; Janssens, Rosanne; Whichello, Chiara; Schölin Bywall, Karin et al.

    Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study

    Part of Frontiers in Pharmacology, 2019.

    DOI Uploaded full-text To DiVA

    Open access

  • Whichello, Chiara; van Overbeeke, Eline; Janssens, Rosanne; Schölin Bywall, Karin et al.

    Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US

    Part of Frontiers in Pharmacology, 2019.

    DOI Uploaded full-text To DiVA

    Open access

  • Janssens, Rosanne; Russo, Selena; van Overbeeke, Eline; Whichello, Chiara et al.

    Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

    Part of Patient, p. 513-526, 2019.

    DOI Uploaded full-text To DiVA

    Open access

  • Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Kihlbom, Ulrik

    Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis

    Part of Patient, p. 297-305, 2019.

    DOI Uploaded full-text To DiVA

    Open access

  • Whichello, Chiara; Schölin Bywall, Karin; Mauer, Jonathan; Watt, Stephen J. et al.

    Mapping benefit-risk decision-making processes and identifying decision points with the potential to include patient preference information throughout the medical product lifecycle

    Part of Pharmacoepidemiology and Drug Safety, p. 206-206, 2018.

    DOI To DiVA

    Open access

  • Janssens, R.; Huys, I; van Overbeeke, E.; Whichello, C. et al.

    Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach

    Part of Value in Health, p. A689-A689, 2017.

    DOI To DiVA

  • Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Kihlbom, Ulrik

    Rheumatoid Arthritis Patients’ Perspectives On The Value Of Patient Preferences In Regulatory Decision-Making During Drug Development: A Qualitative Study

    Part of Value in Health, p. A540-A540, 2017.

    DOI To DiVA

  • van Overbeeke, E.; Whichello, C.; Janssens, R.; de Bekker-Grob, E. et al.

    Conditions And Contextual Factors That Influence The Utility And Application Of Patient Preference Studies: A Study Combining Literature And Focus Groups

    Part of Value in Health, p. A690-A691, 2017.

    DOI To DiVA

Methodology, rheumatoid arthritis and patient involvement

Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.

Read interview

Karin Schölin Bywall
Print